Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 4Phase 1/2 3Phase EARLY_PHASE1 1Phase 4 1Phase 3 1

Status

Recruiting 3Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 3Thoracic 1NET 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Smoldering Multiple Myeloma 2Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Multiple Myeloma 1Multiple Endocrine Neoplasia 1Melanoma 1Lung Neoplasms 1Colorectal Neoplasms 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Leflunomide × Clear all
NCT04508790 2026-05-29

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

City of Hope Medical Center

Phase 2 Recruiting
29 enrolled
Plasma cell

Multiple Myeloma

NCT05014646 2026-04-30

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

City of Hope Medical Center

Phase 2 Active not recruiting
27 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT06540937 2024-08-07

Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
50 enrolled
EndocrineNET

Multiple Endocrine Neoplasia, Neuroendocrine Tumors

NCT06229340 2024-01-29

NТО-RAS

N.N. Petrov National Medical Research Center of Oncology

Phase 2 Recruiting
20 enrolled
DermatologicGastrointestinalThoracic

Lung Neoplasms, Melanoma, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03952832 2019-11-14

Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma

City of Hope Medical Center

Phase 2 Withdrawn
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡